Mary Caffrey

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.

The poster session, “Behind the Curtain: How Healthcare Policy Shapes Patient Outcomes,” took place on the final day of the American Heart Association Scientific Session.

Institute for Value-Based Medicine event with City of Hope.

Results bring more competition to treat this genetically driven target for cardiovascular risk.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.

Lead study author Alexander T. Sandhu, MD, MS, of Stanford said the team will evaluate behavior to understand the results.

Posters presented at the American Heart Association Scientific Sessions included results that show how persistent disparities are in cardiovascular (CV) health.

Payers and employers have tightened access to the glucagon-like peptide 1 receptor agonist class once these therapies became more commonly prescribed for obesity.

The key driver in both sets of findings is the relationship between neutrophils and inflammation.

Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart Association (AHA) Scientific Sessions November 16-18, 2024, which will take place in Chicago, where the AHA was founded 100 years ago.

Authors found the pharmacy costs for momelotinib were $11,095 higher per month, too much to offset higher transfusion costs for ruxolitinib.

Symptomatic improvement on therapy for myeloproliferative neoplasms (MPNs) is very much based on the individual. Data does show momelotinib not only improved spleen size and anemia but also improved symptomatic burden.

Being married and having insurance can offer emotional support and financial stability to lead to early diagnosis and effective treatment, the authors found.

Therapy selection for younger patients with myeloproliferative neoplasms (MPNs) may be different based on the desire for fertility preservation, but they are also at greater risk of their disease progressing, explained Ruben Mesa, MD, FACP, of Atrium Health.

Experts are asking whether the study and treatment of myeloproliferative neoplasms (MPNs) is ready for a new era with new end points, with data that show how survival benefits are biologically linked to changes in the spleen, reduction in fibrosis, or other responses.

There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.

A review of positions and track records of Vice President Kamala Harris and former President Donald Trump on reproductive health, the future of the Affordable Care Act, prescription drug costs, health care consolidation, and a proposed Medicare home health benefit.

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other treatments for polycythemia vera.

Lalan Wilfong, MD, a 20-year medical oncologist with Texas Oncology, is senior vice president, value-based care, Thyme Care.

Attendees at the International Myeloma Society 21st Annual Meeting & Exposition got an early look at data for an investigational allogeneic chimeric antigen receptor (CAR) T-cell product from healthy donor cells to prevent graft-versus-host disease.

Ajai Chari, MD, covered both recent FDA approvals and pipeline products, such as non-BCMA chimeric antigen receptor (CAR) T-cell therapies and trispecifics, during a symposium on Immunotherapy at the International Myeloma Society 21st Annual Meeting & Exposition.

Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease (MRD) negativity testing in an abstract presented at the International Myeloma Society 21st Annual Meeting & Exposition.

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab for patients with newly diagnosed multiple myeloma.